Morgan Stanley Maintains Overweight on State Street, Lowers Price Target to $86
Morgan Stanley analyst Betsy Graseck maintains State Street (NYSE:STT) with a Overweight and lowers the price target from $106 to $86.
Oppenheimer Maintains Outperform on Focus Finl Partners, Lowers Price Target to $52
Oppenheimer analyst Owen Lau maintains Focus Finl Partners (NASDAQ:FOCS) with a Outperform and lowers the price target from $60 to $52.
The Daily Biotech Pulse: FDA Decision On Biogen Alzheimer’s Drug Due In January, FDA Reviews Roche’s Lymphoma Candidate, Rare Pediatric Tag For Kazia’s Pediatric Brain Cancer Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours:
Canaccord Genuity Maintains Buy on VSE, Lowers Price Target to $50
Canaccord Genuity analyst Austin Moeller maintains VSE (NASDAQ:VSEC) with a Buy and lowers the price target from $64 to $50.
Morgan Stanley Maintains Equal-Weight on Reinsurance Group, Lowers Price Target to $131
Morgan Stanley analyst Nigel Dally maintains Reinsurance Group (NYSE:RGA) with a Equal-Weight and lowers the price target from $132 to $131.
Morgan Stanley Maintains Equal-Weight on Prudential Financial, Lowers Price Target to $103
Morgan Stanley analyst Nigel Dally maintains Prudential Financial (NYSE:PRU) with a Equal-Weight and lowers the price target from $120 to $103.
Morgan Stanley Maintains Equal-Weight on Principal Finl Gr, Lowers Price Target to $65
Morgan Stanley analyst Nigel Dally maintains Principal Finl Gr (NASDAQ:PFG) with a Equal-Weight and lowers the price target from $72 to $65.
Morgan Stanley Maintains Equal-Weight on Primerica, Lowers Price Target to $132
Morgan Stanley analyst Bob Huang maintains Primerica (NYSE:PRI) with a Equal-Weight and lowers the price target from $148 to $132.
If You Had Crypto In Voyager Here’s How You Can Get It Back
Voyager Digital CEO Stephen Ehrlich has confirmed that customers with U.S. dollar deposits on its brokerage platform will receive access to funds after the completion of a fraud prevention process.
Qualigen Therapeutics Announces Partnership With Hande Sciences To Scale-Up Manufacturing To Support IND-Enabling Studies For QN-302
Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing